SUMMARY -Carbamazepine and amiodarone may often be used together, especially in countries where cardiomyopathies are common. In this study single doses of carbamazepine (400 mg) were given to patients with cardiac disease before and after one month of therapy with amiodarone, 400 mg daily. The kinetic profile of carbamazepine, its free fraction, and serum amiodarone, were measured at the two occasions. There was no statistically significant change in carbamazepine kinetics or free fraction, before and after the introduction of amiodarone. The concentrations of amidarone after one month of therapy were low. It is sugested that the possible interaction in the hepatic metabolism was not demonstrated because amiodarone concentrations were not enough to inhibit carbamazepine metabolism.
The present study was designed to investigate this interaction and to exclude the possibility of other interactions at the levels of absorption, plasma protein-binding, and at the brain.
MATERIAL AND METHODS
The study was prospective and controlled, each patient serving as its own control. The ethic principles of clinical investigation specified in the Helsinki declaration and its ammendments were followed.
Five men and four women aged between 38 and 70 years (58.4±8.94, mean±standard deviation) were included on the study. Their weight varied between 58-79kg (mean=69.7kg). Two patients suffered of Chagas' disease, and the rest had ischaemic cardiomyopathy-related arrythmias. In 6 cases this was premature ventricular contractions; in two cases it was high frequency supraventricular tachycardia and one patient has sinus arrythmia. Patients were admitted to hospital before and one month after starting therapy with amiodarone (200 mg, orally). The dose of carbamazepine (400 mg, orally) was given 72 hours before amiodarone in the first admission and between 8 and 12 hours after amiodarone on the second. Patients did not change their therapeutic regimens while taking part in the study. Throughout the study they received amiodarone 200 mg orally every 12 hours. On the two occasions they received a single dose of carbamazepine (400 mg, orally), and blood samples were collected before and 1,2,4,6,8,12,24,48 and 72 hours after administration.
After centrifugation serum samples were kept at -20°C until determination of serum concentration of carbamazepine and amiodarone by high performance liquid chromatography 1 . Area under the curve in the time X concentration graph of carbamazepine was measured using the linear trapezoidal rule. Statistical significance was tested using paired Student's t-test with p<0.05 being the minimum level of statistical significance. Plasma protein binding was determined by equilibrium dialysis at pH 7.4 and 37°C using trace amounts of 14°C carbamazepine on at least four of the plasma samples collected on each occasion. Serum concentrations of amiodarone/des-ethylamiodarone were determined by high performance liquid chromatography 11 .
Patients were fully examined and investigated during both admissions. Between 4 and 8 hours after the administration of carbamazepine patients were examined for signs and symptoms of toxicity such as dizziness, nausea, somnolence, diplopia, ataxia, tremor, vertical and horizontal nystagmus, smooth pursuit eye movements. These findings were quantified as absent, discrete, moderate or severe 6 . Figure 1 shows results of total carbamazepine concentrations in the 9 patients before and during amiodarone (200 mg, orally). The rate of absorption was relatively slow with a time to peak of 9.0±6.6 (mean±sd) h before and 7.3±2.4 h, during amiodarone therapy. Table 1 shows areas under the curve and k elimination constants of carbamazepine before and during amiodarone. Table 2 shows the free fractions of carbamazepine before and after one month of amiodarone therapy. Serum concentrations of amiodarone and its metabolite are shown on Table 3 . There were no signs of toxicity before and until 8 hours after administration of carbamazepine in either admission. Clinical, laboratory and radiological investigations (chest X-ray, ECG, full blood count, ESR, creatinine, blood sugar) did not show significant changes except in arrhythmias between the two admissions. Area under the curve for carbamazepine given alone was 1667.5±415.2 (mean±standard deviation) umol/l/h. Therapeutic concentrations were reached in patients 4,5 and 9. Patient 9 had therapeutic serum concentrations for 24 hours. The plateau of serum concentrations between 12 and 24 hours (15.9±5.2 umol/1, mean±standard deviation) was relatively low, and 72 hours after administration carbamazepine was still present in the blood. Terminal half-life elimination was 34±8h. before and 37±9 h during amiodarone therapy. The free fraction of carbamazepine was 0.325±0.035 before and 0.323±0.040 after treatment with amiodarone.
RESULTS
AUC during amiodarone was 1615.3±492.8 (mean±sd) umol/l/h. There was no significant change compared to before amiodarone (p>0.05). Therapeutic serum concentrations were reached in the same 3 patients as before but also by Patient 3 during amiodarone therapy. The plateau of serum concentrations was approximately 18 umol/1 (mean) between 12 and 24 hours after administration.
COMMENTS
Although amiodarone has been used as an antiarrhythmic agent for over a decade knowledge about its kinetics is recent and incomplete 14 . It is slowly absorbed, with a peak serum concentration between 4 and 5 hours after oral administration. The bioavailability is low in view of the dissolution at the intestinal mucosa. In the circulation it is highly bound to proteins. Limits of "therapeutic" serum concentrations are difficult to determine. The lower limit has been estimated at the levels where there is recurrence of arrhythmia after amiodarone withdrawal, between 0.5 and 1.0 ug/ml. Maximum therapeutic concentrations are unknown because months may elapse after the concentrations have reached a plateau and side-effects appear. Amiodarone leaves plasma rapidly and distributes throughout body tissues, mainly liver, lungs, heart and fat 10 . Only after equilibrium antiarrhythmic effect is seen, between 10 and 60 days after oral maintenance doses. When a quicker effect is needed it is important to start with loading doses. Plasma concentrations after oral administration are erratic until at least 4 or 6 weeks after maintenance or loading doses 18 . Elimination is biphasic and terminal elimination half-life exceptionally long, between 8 and 107 days 2 , 9 1 2 , 1 7 . Amiodarone is metabolized predominantly in the liver. There are two well-known metabolites, dides-ethyl-amiodarone and des-ethyl-amiodarone, the latter found in man, although its clinical activity is unknown. During long-term therapy concentration of des-ethyl-amiodarone is one or two times greater than that of amiodarone. The relationship of the plasma concentration of des-ethylamiodarone/amiodarone is useful to evaluate compliance to short term therapy 10 . The side-effects of amiodarone appear mostly during chronic treatment and involve the cardiac, neurologic, and ocular systems, the skin and thyroid gland.
Carbamazepine is used for epileptic disorders, trigeminal and other neuralgias and for some psychiatric disturbances. Its absorption after oral administration is slow 17 and serum concentrations fluctuate widely during absorption, probably in relation to slow dissolution in the gastrointestinal fluid and in relation to its anticholinergic action during chronic treatment, which slows the time of gastrointestinal transit 18 . Peak plasma or serum concentrations are reached between 4 and 8 hours after ingestion, but later peaks between 24 and 32 hours have been reported. The relationship between oral dose and serum concentrations has been shown to be linear in some instances, and nonlinear in others 16 . Bittencourt and Richens 6 demonstrated a linear relationship between serum concentration and effect on saccadic eye movements, but not between serum concentrations and the slower smooth pursuit eye movements, eventhough both were significantly impaired in healthy subjects after a single dose 6 . In the circulation 75% is bound to plasma proteins. Carbamazepine induces an increase in quantity of cytochrome p-450 during long-term therapy decreasing the plateau serum concentrations, the phenomenon known as auto-induction. In healthy subjects the half-life varies between 18 and 55 hours and total clearance between 0.0011 and 0.0210 1/kg/h after a single dose 15 . Side-effects are frequent and usually not severe. They include somnolence, ataxia, dizziness, nystagmus, diplopia, slurred speech and headache
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.
When the results of the present study are compared to those of comparable studies it may be noticed that absorption of carbamazepine is slower in middle aged cardiac patients than in healthy young individuals, aged 25±4.2 years 7 , who after an oral dose of 400mg developed serum concentrations respectively of 8. 5,15.3, 18.1, 21.5 and 19.6 umol/1 at 1,2,4,6 and 8 hours. When these results, observed after doses of 400 mg, are compared to those observed after a single oral dose of 600 mg 1 3 given to neurological inpatients aged 40±19.3 years, it may be noticed that the greater oral dose produces therapeutic serum concentrations at 4 hours (22.3 umol/1), which continue rising at 6 hours (27. 3 umol/1) and at 8 hours (31.5 umol/1, means) . These findings are generally in disagreement with pharmacokinetic concepts that at the extremes of age the possibility of toxicity is greater. Few studies of carbmazepine kinectics in cardiac or elderly patients have been carried out 15 .
An absorption interaction between amiodarone and carbamazepine is difficult to be predicted since amiodarone undergoes desalkilation in the intestinal mucosa while carbamazepine undergoes a slow dissolution in gastrointestinal fluids. An interaction at plasma protein binding sites can be ruled out by the present results, but it might have been an alternative explanation for the initial clinical observation that led to the study. We would like to put forward the hypothesis that an interaction at the hepatic metabolism between amiodarone and carbamazepine was not demonstrated in this study because amiodarone serum concentrations were not sufficient to inhibit the metabolism of carbamazepine. In order for this interaction to be properly demonstrated we suggest that the dosage regimen of Siddoway and colleagues 18 be followed. In this scheme, 2000 mg amiodarone should be given to adults on the first day, 1400 mg daily over the second, third and fourth days, followed by 1000 mg daily for a week, 800 mg daily for 2 weeks, and 600 mg daily for 4 weeks. After this time, maintenance could be kept with 400 mg or 600 mg daily. The possibility that severe side-effects may occurr at this dose should be kept in mind.
